Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline US Deferred Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share acquisition transactions.
| Transaction Type | Price per ADS | Date of Dividend Re-investment |
|---|---|---|
| Acquisition of ADSs via Dividend Re-investment | $38.74 | October 1, 2015 |
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document solely discloses the following share acquisitions:
- Dr M M Slaoui: 310.421 ADSs
- Mr D E Troy: 417.636 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of ADSs held by Dr M M Slaoui and Mr D E Troy following these acquisitions.
- Confirm the dividend payment date of October 1, 2015, and the corresponding re-investment price of $38.74 per ADS.
- Review the full terms of the GlaxoSmithKline US Deferred Performance Share Plan to understand the mechanics of these automatic re-investments.